Yushi Hirota, Yasumasa Kakei, Junta Imai, Hideki Katagiri, Ken Ebihara, Jun Wada, Junichi Suzuki, Tatsuhiko Urakami, Takashi Omori, Wataru Ogawa. A multicenter, open-label, single-arm trial of the long-term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE-02). Journal of diabetes investigation. 2024
Ritsu Akatani, Norio Chihara, Shusuke Koto, Sotaro Mori, Takuji Kurimoto, Makoto Nakamura, Hisatsugu Tachibana, Yoshihisa Otsuka, Takehiro Ueda, Takashi Omori, et al. Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study. Immunological medicine. 2024. 1-8
Yushi Hirota, Yasumasa Kakei, Junta Imai, Hideki Katagiri, Ken Ebihara, Jun Wada, Junichi Suzuki, Tatsuhiko Urakami, Takashi Omori, Wataru Ogawa. A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01). Diabetes therapy : research, treatment and education of diabetes and related disorders. 2024. 15. 2. 533-545
Takashi Omori, Makoto Hayashi. The assessment and communication of genotoxicity test results: moving beyond binary. Mutation research. Genetic toxicology and environmental mutagenesis. 2024. 893. 503722-503722
Kandai Nozu, Mayumi Sako, Seiji Tanaka, Yuji Kano, Yoko Ohwada, Tamaki Morohashi, Riku Hamada, Yasufumi Ohtsuka, Masafumi Oka, Koichi Kamei, et al. Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome: a multicenter single-arm clinical trial (JSKDC11 trial). Clinical and experimental nephrology. 2023. 28. 4. 337-348
